ICER

Showing 1 posts of 1 posts found.

Nucala

Researchers question price of GSK’s Nucala

December 23, 2015
Research and Development GSK, HEOR, ICER, Nucala, asthma, cost-effective, health economics, health economics outcomes research

GSK is charging up to four times more for its recently approved asthma drug Nucala than is justified by cost-effectiveness …

The Gateway to Local Adoption Series

Latest content